"RADICAL" FDA REFORM MEASURE WILL NOT PASS CONGRESS THIS YEAR, KENNEDY STAFFER WARNS; SENATE FAVORS BIPARTISAN APPROACH, IMPROVING CURRENT SYSTEM
This article was originally published in The Gray Sheet
Executive Summary
FDA reform efforts should focus on improving management within the agency and reducing regulatory burdens on manufacturers to speed product approvals, David Nexon, minority staff director for health for the Senate Labor and Human Resources Committee, said at a Feb. 7 conference in Washington, D.C. hosted by the Progress & Freedom Foundation.
You may also be interested in...
Device Reform Legislation Via PDUFA Still A Possibility; Other Vehicles Await
The House Energy & Commerce Committee appears determined to push device reforms through Congress this year, even if Prescription Drug User Fee Act reauthorization does not provide a suitable vehicle
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.